|
Olverembatinib Clinical Trials
11 actively recruiting trials across 2 locations
No change since August 2026
Also known as: 6-MP, Cytarabine, Daunorubicin, Dexamethasone, Methotrexate +5 more
Pipeline
Phase 2: 3Phase 3: 4Phase 1/2: 1
Top Sponsors
- Ascentage Pharma Group Inc.4
- Institute of Hematology & Blood Diseases Hospital, China3
- The First Affiliated Hospital of Soochow University1
- Peking University People's Hospital1
- M.D. Anderson Cancer Center1
Indications
- Cancer11
- Chronic Myeloid Leukemia3
- Ph-Like1
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive1
- Ph+ ALL1
Other8 trials
Birmingham, Alabama2 trials
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ascentage Investigative Site #1044
Phase 3
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Ascentage Investigative Site #1044
Phase 3
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.